trial · primary record
Jaktinib Hydrochloride Tablet
Atopic Dermatitis
| Phase | Phase 3 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 443 |
| Primary completion | 2025-08-05 |
| Primary endpoint | The efficacy in the treatment of moderate and severe atopic dermatitis |
| Registry ID | NCT05526222 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:44.258Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05526222
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Jaktinib Hydrochloride Tablet · compound